retatrutide clinical trials sign up Retatrutide, Eli Lilly's next generation of weight loss injections, showed dramatic results in trials, with patients losing an average of to 71.2 pounds, or 28.7% of their body weight. Eli Retatrutide Starting Dose: What Clinical

These receptors stimulate hormones that control blood sugar levels and reduce appetite, triggering weight loss

Retatrutide is not FDA approved, not EMA approved, and has no approved prescription pathway as of April 2026

Placebo: -2.1%

TRIUMPH-CVOT TRIUMPH-CVOT is the cardiovascular outcomes trial and the longest-running part of the program

Crook lost 25 pounds in seven weeks, but stopped because of extreme nausea, though his circumstances are very specific: he was taking a proton pump inhibitor to manage acid reflux he got after taking anabolic steroids

In a major late-stage clinical trial, people taking the highest dose of the experimental drug retatrutide lost an average of 70.3 pounds or 28.3 percent of their body weight over 80 weeks